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Abstract 
The Weibull distribution is a widely used model for studying fatigue and endurance life in engineering devices 
and materials.  Recent advances in Weibull theory have also created numerous specialized Weibull applications.  
Modern computing technology has made many of these techniques accessible across the engineering spectrum.  
Despite its popularity, and wide applicability the traditional 2 – parameter and 3- parameter Weibull distribution 
is unable to capture all the lifetime phenomenon for instance the data set which has a non – monotonic failure 
rate function.  Recently several generalization of Weibull distribution has been studied.  An approach to the 
construction of flexible parametric model is to embed appropriate competing models into a larger model by 
adding  shape  parameter.    Some  recent  generalizations  of  Weibull  distribution  including  the  Exponentiated 
Weibull,  Extended  Weibull,  Modified  Weibull  are  discussed    and  references  [5]  therein,  along  with  their 
reliability functions.  In this paper a new generalization of Weibull distribution called the transmuted Weibull 
distribution is utilized for our medical application. For example, Prolactin and prolactin receptors are present in 
normal  breast  tissue,  benign  breast  disease,  breast  cancer  cell  lines,  and  breast  tumour  tissue,  leading  to 
speculation that the proliferative and antiapoptotic effects of prolactin in breast epithelial cells could be a factor 
in breast carcinogenesis.  In this paper, a test for the distribution of prolactin concentrations in controls, by 
menopausal status and relationships with Serum Prolactin Levels and Breast Cancer Risk was investigated in the 
application  part,  by  using  Transmuted  Weibull  Distribution.    As  a  result  the  mathematical  curves  for  the 
Probability Density Function, Reliability Function and Hazard Rate Function are obtained for the corresponding 
medical curve given in the application part. 
Keywords: Prolactin (PRL), Prolactin Receptor (PRLR), Single Nucleotide Polymorphism(SNP), Transmuted 
Weibull Distribution, Reliability Function, Hazard Rate Function. 
Mathematics Subject Classification: 62N05, 90B25 
 
I.  Mathematical Model 
1.1 Introduction 
Some  recent  generalizations  of  Weibull  distribution  including  the  exponentiated  Weibull,  extended 
Weibull, modified Weibull are discussed  and references [5] therein, along with their reliability functions.  In 
this article a new generalization of Weibull distribution called the transmuted Weibull distribution is presented 
[8]. 
A random variable X is said to have transmuted distribution if its cumulative distribution function is given 
by 
? 𝑥  =  1 + 𝜆 ? 𝑥  − 𝜆?(𝑥)2 , 𝜆  ≤ 1                                                                                             ………………(1.1) 
where G(x) is the cdf of the base distribution.  Observe that at λ = 0 we have the distribution of the base random 
variable. Aryal et al [4] studied the transmuted Gumbel distribution and it has been observed that transmuted 
Gumbel distribution can be used to model climate data.  In the present study we will provide mathematical 
formulation of the transmuted Weibull distribution  and some of  its properties. 
 
1.2 Transmuted Weibull Distribution 
A random variable X is said to have a Weibull distribution with parameters η > 0 and σ > 0 if its probability 
density function is given by  
? 𝑥  = 
𝜂
𝜎
 
𝑥
𝜎
 
𝜂−1
?𝑥? − 
𝑥
𝜎
 
𝜂
 ,𝑥 > 0                                                                                               ……………… 1.2  
The cdf of X is given by  
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? 𝑥  =  1 − ?𝑥? − 
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𝜎
 
𝜂
                                                                                                                        ……………… 1.3  
Now using (1.1) and (1.3) the cdf of a transmuted Weibull distribution is  
? 𝑥  =  1 − ?𝑥? − 
𝑥
𝜎
 
𝜂
   1 + 𝜆?𝑥? − 
𝑥
𝜎
 
𝜂
                                                                             ………………(1.4) 
Hence, the pdf of transmuted Weibull distribution with parameters η, σ and λ is     
? 𝑥  =
𝜂
𝜎
 
𝑥
𝜎
 
𝜂−1
?𝑥? − 
𝑥
𝜎
 
𝜂
  1 − 𝜆 + 2𝜆?𝑥? − 
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                                                                      …………(1.5) 
Note  that  the  transmuted  Weibull  distribution  is  an  extended  model  to  analyze  more  complex  data  and  it 
generalizes some of the widely used distributions.  In particular for η=1we have the transmuted exponential 
distribution as discussed in Shaw et al [8].  The Weibull distribution is clearly a special case for λ = 0.  When  
η = λ = 1 then the resulting distribution is an exponential distribution with parameter 
𝜎
2. 
In this section we shall present the moments and quantiles for the transmuted Weibull distribution.  The k
th 
order moments of a transmuted Weibull random variable X, in terms of gamma function Γ(.) is given by 
  ? 𝑋?  = 𝜎?Γ 1 +
?
𝜂  1 − 𝜆 + 𝜆2
−?
𝜂                                                                                       …… ………(1.6) 
Moreover, if ? 𝜂 = ?    is a positive integer then, 
    ? 𝑋?  = 𝜎??! 1 − 𝜆 + 𝜆2−?  
Therefore, the expected value E(X) and variance Var(X) of a transmuted Weibull random variable X are,  
  ? 𝑋  =  𝜎Γ 1 +
1
𝜂  1 − 𝜆 + 𝜆2
−1
𝜂                                         …………(1.7)  
𝑉𝑎? 𝑋  = 𝜎2  Γ 1 +
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−1
𝜂  
2
                                        …………(1.8) 
Note that when η = k, 
      ? 𝑋?  = 𝜎?  
2−𝜆
2   
The q
th quantile xq of the transmuted Weibull distribution can be obtained from (1.4) as 
𝑥? = 𝜎 −?𝑛 1 −  
1 + 𝜆 −   1 + 𝜆 2 − 4𝜆?
2𝜆
   
1
𝜂
                                                                                 ………… 1.9  
  The transmuted Weibull distribution can be a useful characterization of failure time of a given system 
because of the analytical structure.  The reliability function R(t), which is the probability of an item not failing 
prior to some time t, is defined by R(t) = 1 – F(t).  The reliability function of a transmuted Weibull distribution 
is given by 
𝑅 𝑡  = ?𝑥? − 
𝑡
𝜎
 
𝜂
  1 − 𝜆 + 𝜆?𝑥? − 
𝑡
𝜎
 
𝜂
                                                                              …………… 1.10  
The other characteristic of interest of a random variable is the hazard rate function defined by ? 𝑡  = 
?(𝑡)
1−?(𝑡) 
which is an important quantity characterizing life phenomenon.  It can be loosely interpreted as the conditional 
probability of failure given it has survived to the time t.  The hazard rate function for a transmuted Weibull 
random variable is given by 
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                                                                                 ………………(1.11) 
From equations (1.5), (1.10) & (1.11) the mathematical representations of the Probability Density Function, 
Reliability Function and Hazard Rate Functions are given in Mathematical Result. 
 
II.  Application 
The reproductive hormone prolactin is produced primarily by the pituitary gland [6] and in lesser amounts 
by  several  other  tissues,  including  breast  tissue.    Prolactin  plays  a  central  role  in  breast  development, 
differentiation  and  lactation  [1]  but  experimental  data  suggest  that,  in  addition  to  having  a  role  in  normal 
development, prolactin may have procarcinogenic effects    [2,9].  Prolactin and prolactin receptors are present 
in normal breast tissue, benign breast disease, breast cancer cell lines, and breast tumour tissue, leading to 
speculation that the proliferative and  antiapoptotic effects of prolactin in breast epithelial cells could be a factor 
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There is a growing body of epidemiologic evidence supporting an association between circulating prolactin 
levels and breast cancer risk, although data are not conclusive.  Large prospective studies have reported a 
positive  association  between  prolactin  levels  and  breast  cancer  risk  [10].  No  association  was  reported  by 
smaller prospective studies, although the number of breast cancer cases was limited [13].  Results from case – 
control studies are inconsistent.  It is also found that increased serum prolactin levels were associated with 
nulliparity in premenopausal women and with current or recent use of hormone therapy (HT) and lower body 
mass indices (BMI) in postmenopausal women [3]. 
In addition to reproductive and environmental factors, genetic variation in the prolactin (PRL) and prolactin 
receptor (PRLR) genes may be associated with increased prolactin levels and breast cancer risk.  Exploration of 
genetic variants in prolactin and prolactin receptor has identified single – neucleotide polymorphisms (SNPs) 
that alter transcription factor binding, modify prolactin receptor activity, and may be associated with breast 
cancer risk [11] or circulating prolactin levels.  In a recent study of finding the relationship between serum 
prolactin and breast cancer risk, it is investigated that the association between common genetic variation in  
prolactin and prolactin receptor and breast cancer in the Breast Cancer Study.  Additionally, the association 
between prolactin and prolactin receptor single – neucleotide polymorphisms and serum prolactin levels among 
controls,  hypothesizing  that  altered  serum  prolactin  levels  may  be  an  intermediate  marker  between  genetic 
variation in prolactin and prolactin receptor and breast cancer risk.  
 
2.1 Study population 
Briefly, eligible cases included women (age range of 20 to 74 years) whose primary invasive or in situ 
breast cancer was diagnosed.   Cases were identified by means of a rapid identification system.  Eligible controls 
were identified from a population registry containing demographic information and were frequency – matched 
to cases on the basis of age (5 –year categories) and study site.  A total of  2,502 controls (69% of eligible) were 
enrolled in the study. 
Study  participants  provided  information  on  demographics,  reproductive  and  medical  history,  oral 
contraceptive and postmenopausal hormone use, and other potential breast cancer risk factors.  A blood sample 
was provided by 84% of cases and 92% of controls. 
 
2.2 Serum Prolactin Measurement 
Serum  prolactin  concentration  was  measured  in  a  subset  of  cases  and  controls,  whose  selection  was 
described in detail by Faupel – Badger and colleagues [3].  Controls were matched to cases by menopausal 
status, age (5- year categories), time of blood collection (within 2 hours) study site, and day of menstrual cycle 
(within 2 days, premenopausal women only).  Only control prolactin concentration were used in this analysis. 
Serum  prolactin  levels  were  measured  by  Quest  Diagnostics  by  using  the  Bayer  ADVIA  Centaur 
Immunoassay and were calculated after caliberation with known prolactin concentrations.  One control subject 
was excluded from  further  serum prolactin analyses because of a concentration outside the assay limits of 
detection(0.3 to 200 ng/mL). 
Women were classified as premenopausal if they reported that they were still having natural menstrual 
periods; medical records were used to determine menopausal status for women who did not know whether they 
were still experiencing natural menstrual periods.  Among postmenopausal women, oral hormone therapy use 
was based on self – reported use of estrogen and progesterone pills for purposes other than birth control. Family 
history of breast cancer was based on female first – degree relatives with breast cancer.  
Time of blood collection was included in models by using 2 – hour categories.  Time since last menstrual 
period was the number of days between blood draw and the participant’s most recent menstrual period and was 
used as a continuous variable. 
Previous  studies  have  shown  that  prolactin  levels  are  higher  in  premenopausal  compared  with 
postmenopausal women and that prolactin levels vary with the day of menstrual cycle in premenopausal women.  
Owing  to  the  differences  in  average  prolactin  levels  and  cycling  patterns,  the  data  are  presented  on  mean 
prolactin levels by genotype stratified by menopausal status.  Models were adjusted for age, time of  blood 
collection, and time since last menstrual period (premenopausal women only).  
 
2.3 Association between Prolactin, Prolactin Receptor Single – Neucleotide Polymorphisms and Breast 
Cancer Risk 
By examine the association between variant alleles in 25 single neucleotide polymorphisms – 7 prolactin 
and  18 prolactin receptor   and breast cancer risk, prolactin receptor   single  – neucleotide polymorphisms 
rs7718468  and  rs13436213  were  associated  with  postmenopausal  breast  cancer  risk.      For  both  single  – 
neucleotide polymorphisms, the association was strongest for women carrying the minor allele homozygous 
genotype.  One single – neucleotide polymorphism was associated with premenopausal breast cancer. M. Goperundevi Int. Journal of Engineering Research and Applications                        www.ijera.com 
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Serum prolactin was measured in 773 controls, and levels were higher in premenopausal women compared 
with postmenopausal women (Figure 2.3.1).  Several single – neucleotide polymorphisms in prolactin receptor 
were  significantly  associated  with  prolactin  levels  in  premenopausal  controls.    Closer  examination  of  the 
prolactin distributions showed that there was several outlier values among postmenopausal controls, and so it is 
necessary to perform a sensitivity analysis to determine the effect of these outliers on the association between 
rs849872 and prolactin in postmenopausal controls (Figure 2.3.1) 
A sliding window approach was used to identify global haplotype associations with breast cancer.  An 
association was detected for a region encompassing prolactin receptor  single – neucleotide polymorphisms 
rs873456, rs7718468, rs34024951, and rs9292575 and postmenopausal breast cancer.  Five haplotypes in this 
region had estimated frequencies of greater than 0.05, and haplotype G-C-G-C was positively associated with 
breast cancer risk when compared with the referent haplotype G-T-G-C.  These haplotypes were not associated 
with serum prolactin levels in postmenopausal controls.  There was no association between prolactin receptor 
haplotypes  and  premenopausal  breast  cancer  or  between  prolactin  haplotypes  and  premenopausal  or 
postmenopausal breast cancer. 
 
The distribution of serum prolactin concentrations in controls, by menopausal status 
 
Figure 2.3.1 
 
Prolactin concentrations in Breast Cancer Study control subjects ranged from 2.1 to 348.4 ng/mL and the 
majority  were  less  than  50  ng/mL.    The  unadjusted  geometric  mean  (interquartile  range)  prolactin 
concentrations were 10.89 ng/mL (7.80 to 15.30) in premenopausal controls and 6.99 ng/mL (5.30 to 8.60) in 
postmenopausal controls.  
Several breast cancer risk factors have been reported to be associated with prolactin levels [7] and estrogen 
has been shown to stimulate the prolactin extrapituitary promoter in breast cancer cell  lines.  Furthermore, 
prolactin  act  through  both  autocrine  and  endocrine  pathways.    Refinement  of  tissue  –  level  prolactin  and 
prolactin receptor expression assays may provide a more accurate estimate of the prolactin levels surrounding 
breast epithelial cells from autocrine and endocrine sources. 
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III.  Mathematical Results 
 
 
 
 
Figure 3.1 
In testing the distribution of serum prolactin concentrations in controls, by menopausal status: The Probability 
Density Function f(x) increases in the interval of 15 to 30 minutes and it decreases suddenly from the 30
th 
minute to the end (2
nd hour) 
 
 
Figure 3.2 
In testing the distribution of serum prolactin concentrations in controls, by menopausal status: The Reliability 
Function R(t) reaches its maximum value in the 15
th minute and it decreases gradually from the 15
th minute to 
the end (2
nd hour. 
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Figure 3.3 
In testing the distribution of serum prolactin concentrations in controls, by menopausal status:  
The Hazard Rate Function h(t) increases from the 15
th minute till the end (2
nd hour).  
 
IV.  Conclusion 
As a result the curves for the PDF, Reliability Function and the Hazard Rate Function are obtained in 
Figures  (3.1,  3.2  &  3.3)  for  the  corresponding  medical  figure  given  in  the  application  part.    During  the 
investigation of serum prolactin concentrations (in a period of 2hours) the Hazard Rate Function increases from 
the 15
th minute till the end (2
nd hour), the PDF increases in the interval of 15 to 30 minutes and it decreases 
suddenly from the 30
th minute to the end (2
nd hour) and the Reliability Function reaches its maximum value in 
the 15
th minute and it decreases gradually from the 15
th minute to the end (2
nd hour).  In this study it is observed 
that:  In testing the distribution of serum prolactin concentrations in controls, by menopausal status the hazard 
rate density is found to be higher for premenopausal stage than the postmenopausal stage.  Thus, the Genetic 
Variation of Prolactin and Prolactin Receptor in Relationship with Serum Prolactin Concentrations and Breast 
Cancer Risk is more for the Premenopausal Cases and very low for Postmenopausal cases.  
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